Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD1 | Q13393 | 1/20 | 0.55 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.55 |
| ▸ | SLC39A7 | Q92504 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.39 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27048955 | 0.86 | PDE7A (0.58) | PLD1PDE7ASLC39A7HRH3AKR1B1 | |
| SCHEMBL13314944 | 0.82 | PDE7A (0.55) | PLD1PDE7ASLC39A7HRH3AKR1B1 | |
| SCHEMBL9912018 | 0.81 | PDE7A (0.67) | PLD1PDE7AAKR1B1 | |
| SCHEMBL30800280 | 0.81 | PLD1 (0.59) | PLD1PDE7ASLC39A7HRH3HTR2A | |
| SCHEMBL14156534 | 0.80 | PDE7A (0.61) | PLD1PDE7ASLC39A7AKR1B1 | |
| SCHEMBL17779117 | 0.79 | HRH3 (0.59) | PLD1HRH3CCR5HTR2A | |
| SCHEMBL13052383 | 0.78 | PDE7A (0.58) | PLD1PDE7ASLC39A7HTR2ATP53 | |
| SCHEMBL3281974 | 0.78 | TP53 (0.60) | PLD1HRH3TP53CYP3A4MAPT | |
| SCHEMBL13068678 | 0.76 | PDE7A (0.67) | PLD1PDE7AAKR1B1 | |
| SCHEMBL8226037 | 0.75 | OPRL1 (0.66) | PLD1PDE7AOPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152176-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152176-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-17 | — | — | US | disclosed |
| US-7696201-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696201-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080176843-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-24 | — | — | US | disclosed |
| US-20080176843-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176843-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | PLD1 1313/4885PDE7A 290/4885SLC39A7 3717/4885 |
| US-20100152176-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | PLD1 1313/4885PDE7A 290/4885SLC39A7 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.